Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes

Probably not a substantial claim: may not pass S3 (load-bearing).

LDL biology is mostly relevant for peripheral diseases.

“While LDL biology is mostly relevant for peripheral diseases32,54,55”

• cites [32] Mahley, 1999, Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes, J. Lipid Res. sourceNot checked — no full text of the source
• cites [54] Brown, 1983, Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic, J. Clin. Invest. sourceDisputed

  The paper emphasizes hepatic LDL receptors rather than presenting LDL biology as mostly peripheral. In “Control Signals for Plasma Cholesterol Traffic” (pp. 1–2), it says that more than half of LDL receptors are in the liver and that changes in hepatic receptor activity alter plasma LDL levels. It also discusses extrahepatic tissues and atherosclerosis, but does not characterize LDL biology as mostly relevant to peripheral diseases. (LLM, conf=0.75)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites [55] Herz, 1995, Lipoprotein and receptor interactions in vivo, Curr. Opin. Lipidol. sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

ApoE has been implicated in various cellular pathways linked to AD pathogenesis, including amyloid-β (Aβ) clearance and aggregation, tau pathology, metabolism, endolysosomal trafficking, and neuroinflammation.

“Apolipoprotein E (ApoE) has been implicated in various cellular pathways linked to AD pathogenesis, including amyloid-β (Aβ) clearance and aggregation, tau pathology, metabolism, endolysosomal trafficking, and neuroinflammation1–3.”

• cites [1] Martens, 2022, ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias, Neuron sourcePartly supported

  The Phenotypic phase links apoE to Aβ aggregation, tau pathology, and neuroinflammation; the Cellular phase describes apoE4-related endosomal trafficking dysregulation, and the Concluding remarks identify lipid metabolism as another apoE pathway. The passages found do not establish the specific claim about Aβ clearance. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [2] Johnson, 2020, APOE and metabolic dysfunction in Alzheimer's disease, Int. Rev. Neurobiol. sourceNot checked — no full text of the source
• cites [3] Windham, 2024, The cell biology of APOE in the brain, Trends Cell Biol. sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

APOE genotype is the most significant genetic modifier for late onset Alzheimer's disease (LOAD), with APOE4 and APOE2 alleles greatly increasing and decreasing disease risk, respectively, relative to the more common APOE3 allele.

“APOE genotype is the most significant genetic modifier for late onset Alzheimer’s disease (LOAD), with APOE4 and APOE2 alleles greatly increasing and decreasing disease risk, respectively, relative to the more common APOE3 allele1.”

• cites [1] Martens, 2022, ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias, Neuron sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

ApoE is the most abundant apolipoprotein in the brain, where it is primarily expressed by astrocytes and reactive microglia, regulating cholesterol metabolism.

“ApoE is the most abundant apolipoprotein in the brain, where it is primarily expressed by astrocytes and reactive microglia7, regulating cholesterol metabolism8,9.”

• cites [7] Fernandez, 2019, The role of APOE4 in disrupting the homeostatic functions of astrocytes and microglia in aging and Alzheimer's disease, Front. Aging Neurosci. sourcePartly supported

  The Overview of APOE Isoforms (page unavailable) says APOE is predominantly expressed by astrocytes and microglia, and the section on the microglial phenotype in AD reports increased APOE expression in disease-associated microglia. The copy does not establish that APOE is the brain’s most abundant apolipoprotein. The cholesterol-metabolism clause has separate citations (8 and 9) and is not attributed to this source. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [8] Cantuti-Castelvetri, 2018, Defective cholesterol clearance limits remyelination in the aged central nervous system, Science sourcePartly supported

  The main text (p. 2) calls ApoE the major CNS cholesterol carrier and says astrocytes produce it. It studies wild-type and ApoE-knockout microglia (Supplementary Materials, p. 6), but does not establish that reactive microglia primarily express ApoE or that it is the brain’s most abundant apolipoprotein. The cholesterol-metabolism clause is cited to other sources in the citing sentence. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [9] Nugent, 2020, TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge, Neuron sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

In disease models, ApoE4 perturbs cholesterol regulation, including expression of cholesterol metabolism-related genes, cholesterol transport and esterification.

“In disease models, ApoE4 perturbs cholesterol regulation, including expression of cholesterol metabolism-related genes, cholesterol transport and esterification10–13.”

• cites [10] Litvinchuk, 2024, Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist, Neuron sourceNot checked — no full text of the source
• cites [11] Lin, 2018, APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived brain cell types, Neuron sourcePartly supported

  The Discussion (‘APOE4 effects on astrocytes’; page not supplied) reports altered expression of lipid-metabolism and transport genes and cholesterol accumulation in APOE4 astrocyte cultures. The Results (‘APOE4 astrocytes exhibit compromised Aβ uptake’; page not supplied) also report altered lipid-transport gene expression and cholesterol levels. Our copy does not report an effect on cholesterol esterification, so that specific part of the claim is unsupported. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [12] Blanchard, 2022, APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes, Nature sourceSupported
• cites [13] Tcw, 2022, Cholesterol and matrisome pathways dysregulated in astrocytes and microglia, Cell sourcePartly supported

  The Results sections on altered lipid metabolism and impaired cholesterol trafficking report APOE4-related changes in cholesterol-metabolism gene expression, transporters, and efflux in astrocytes and microglia. They do not establish perturbed cholesterol esterification: the measured increase in astrocyte cholesterol came from free cholesterol, not cholesteryl esters. Page numbers were not available in our copy. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Lipids are central to AD pathogenesis, as suggested by studies showing cholesterol dysregulation in a range of AD models and patients' brains.

“Together with studies showing cholesterol dysregulation in a range of AD models and patients’ brains, these studies suggest lipids are central to AD pathogenesis14–18.”

• cites [14] Chan, 2012, Comparative lipidomic analysis of mouse and human brain with Alzheimer disease, J. Biol. Chem. sourceSupported
• cites [15] van der Kant, 2019, Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-beta in iPSC-derived Alzheimer's disease neurons, Cell Stem Cell sourceSupported
• cites [16] Feringa, 2021, Cholesterol and Alzheimer's disease; from risk genes to pathological effects, Front. Aging Neurosci. sourceSupported
• cites [17] Romero-Molina, 2022, Microglial efferocytosis: diving into the Alzheimer's disease gene pool, Neuron sourcePartly supported

  The sections on AD genetic architecture and cholesterol efflux link disrupted cholesterol metabolism and lipid accumulation to AD risk, and describe lipid droplets in plaque-associated human microglia. They do not establish cholesterol dysregulation across a range of AD models and patients’ brains specifically; the cited mouse findings include demyelination models, and the human-brain finding concerns lipid droplets rather than a direct measure of cholesterol dysregulation. No page numbers were available in our copy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured
• cites [18] Miranda, 2022, Effects of APOE4 allelic dosage on lipidomic signatures in the entorhinal cortex of aged mice, Transl. Psychiatry sourcePartly supported

  The Introduction reports altered brain cholesterol in APOE mouse models and altered lipids in post-mortem brains of AD patients. The patient finding concerns glycerophospholipids, however, not cholesterol; the copy therefore does not establish the claimed cholesterol dysregulation in patients’ brains. The Discussion supports the broader suggestion that lipid dysregulation is implicated in AD. (LLM, conf=0.83)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Reducing ApoE levels is generally protective in AD models.

“Reducing ApoE levels is generally protective in AD models1,4–6.”

• cites [1] Martens, 2022, ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias, Neuron sourcePartly supported

  The Phenotypic phase section reports that apoE deficiency in mice greatly reduces amyloid plaques and cerebral amyloid angiopathy. But the Targeting apoE-initiated cascade events section says that increasing or decreasing apoE protein levels may be appropriate depending on the isoform. The source therefore supports protection in some AD models, not a general protective effect of reducing apoE levels. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [4] Bales, 1997, Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition, Nat. Genet. sourceNot checked — no full text of the source
• cites [5] Huynh, 2017, Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of beta-amyloidosis, Neuron sourcePartly supported

  The Discussion reports that reducing apoE before amyloid deposition decreased Aβ pathology in the mouse models studied. It also reports that treatment begun at the onset of aggregation did not reduce overall amyloid burden, although it reduced neuritic dystrophy; the Abstract notes increased plaque size. Thus the paper supports protective effects under some conditions, but not an unqualified generalization across AD models or treatment times. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [6] Shi, 2017, ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy, Nature sourcePartly supported

  The paper’s Abstract reports that the absence of ApoE was strongly neuroprotective in a P301S mouse model of tauopathy. That supports protection from eliminating ApoE in this model, but not the broader claim that reducing ApoE levels is generally protective across AD models. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

The protective mechanism of the R136S variant has been attributed to reduced binding to heparan sulfate proteoglycans (HSPGs).

“While the protective mechanism of the R136S variant has been attributed to reduced binding to heparan sulfate proteoglycans (HSPGs)24, it is unclear if it involves the lipidated state of ApoE.”

• cites [24] Arboleda-Velasquez, 2019, Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report, Nat. Med. sourceSupported

Classified as probably not a substantial claim.

A mildly protective effect of the heterozygous Christchurch mutation was found in the same kindred.

“A mildly protective effect of the heterozygous Christchurch mutation was also found in the same kindred25.”

• cites [25] Quiroz, 2024, APOE3 Christchurch heterozygosity and autosomal dominant Alzheimer's disease, N. Engl. J. Med. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Elevated CE levels have been reported in AD brains and AD models.

“Elevated CE levels have been reported in AD brains as well as AD models12,14,15.”

• cites [12] Blanchard, 2022, APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes, Nature sourcePartly supported

  The Introduction reports significantly increased cholesteryl ester species in APOE4/4 iPSC-derived oligodendroglia, supporting the AD-model portion. In human brain tissue, it reports only a nonsignificant trend in a small APOE4/4 comparison; its separate significant finding was in people without AD pathology. It therefore does not establish elevated CE levels in AD brains generally. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [14] Chan, 2012, Comparative lipidomic analysis of mouse and human brain with Alzheimer disease, J. Biol. Chem. sourceSupported
• cites [15] van der Kant, 2019, Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-beta in iPSC-derived Alzheimer's disease neurons, Cell Stem Cell sourceSupported

Classified as probably not a substantial claim.

CNS lipoproteins are HDL-like.

“As CNS lipoproteins are HDL-like16, we next tested if ApoE isoforms differentially mediate cellular uptake of pHrodo-labeled HDL pre-complexed with non-lipidated ApoE before addition to serum-starved H4 cells.”

• cites [16] Feringa, 2021, Cholesterol and Alzheimer's disease; from risk genes to pathological effects, Front. Aging Neurosci. sourceSupported

Classified as probably not a substantial claim. May combine two claims.

A homozygous APOE3 Christchurch mutation (R136S) carrier presented a ~30-year delay in dementia onset caused by the PSEN1 E280A mutation and limited tau pathology despite abundant amyloid burden.

“Recently, a study reported a homozygous APOE3 Christchurch mutation (R136S) carrier presenting a ~30-year delay in dementia onset caused by the PSEN1 E280A mutation and limited tau pathology despite abundant amyloid burden24.”

• cites [24] Arboleda-Velasquez, 2019, Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report, Nat. Med. sourcePartly supported

  The Abstract describes a PSEN1 E280A carrier homozygous for APOE3 Christchurch (R136S) who developed mild cognitive impairment nearly three decades later than expected, with high amyloid burden and limited tau pathology. It does not establish a 30-year delay specifically in dementia onset; the authors say they cannot determine whether her resistance to dementia reflects delayed impairment, prolonged impairment, or both. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

The compensatory upregulation of LDLR expression was most pronounced in astrocytes as this cell type is equipped with efficient cholesterol efflux machinery.

“The compensatory upregulation of LDLR expression was most pronounced in astrocytes as this cell type is equipped with efficient cholesterol efflux machinery31.”

• cites [31] Chen, 2013, Cholesterol efflux is differentially regulated in neurons and astrocytes: implications for brain cholesterol homeostasis, Biochim. Biophys. Acta sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Lipid challenges, including cholesterol, can induce pro-inflammatory responses in microglia.

“Lipid challenges, including cholesterol, can induce pro-inflammatory responses in microglia8,9,33.”

• cites [8] Cantuti-Castelvetri, 2018, Defective cholesterol clearance limits remyelination in the aged central nervous system, Science sourcePartly supported

  The main text (pp. 2–3) reports that cholesterol-rich myelin debris can activate inflammasomes and drive a maladaptive inflammatory response in phagocytes. The experiments described on p. 2 identify macrophages, not microglia specifically, and do not establish the same response to lipid challenges generally. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [9] Nugent, 2020, TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge, Neuron sourceNot checked — no full text of the source
• cites [33] Andreone, 2020, Alzheimer's-associated PLCgamma2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia, Nat. Neurosci. sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

Increasing evidence suggests ApoE4 promotes spreading of tau pathology in AD brains.

“Increasing evidence suggests ApoE4 promotes spreading of tau pathology in AD brains38,39.”

• cites [38] Ferrari-Souza, 2023, APOEepsilon4 potentiates amyloid beta effects on longitudinal tau pathology, Nat Aging sourceSupported
• cites [39] Steward, 2023, ApoE4 and connectivity-mediated spreading of tau pathology at lower amyloid levels, JAMA Neurol. sourceSupported

May combine two claims.

The K146E mutation impairs both LDLR and HSPG binding.

“we exploited the K146E mutation, which impairs both LDLR and HSPG binding36.”

• cites [36] Mann, 1995, Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu), J. Clin. Invest. sourcePartly supported

  The Results report impaired LDL-receptor binding and show that K146E binding to heparin fell to 10% of normal. Heparin was used as a model for cell-surface proteoglycans; the Discussion proposes impaired binding to HSPG but does not report a direct HSPG-binding test. The claim states that proposed impairment as an established finding. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

PUFAs are peroxidation-prone and may facilitate the formation of neuronal lipofuscin, a lysosomal pathology that is a hallmark of aging.

“Since PUFAs are peroxidation-prone and may facilitate the formation of neuronal lipofuscin, a lysosomal pathology that is a hallmark of aging35, we generated ApoE particles consisting of POPC and CE(20:4) (CE(20:4)-lipApoE) (Figure S5B–C) and tested if ApoE isoforms can differentially modulate lipofuscin accumulation in human iPSC-derived neurons (iNeurons) (Figure S5D).”

• cites [35] Moreno-García, 2018, An overview of the role of lipofuscin in age-related neurodegeneration, Front. Neurosci. sourcePartly supported

  The “Alzheimer’s disease” section says lipid-peroxidation products contribute to lipofuscin formation and describes polyunsaturated fatty acids being attacked in erythrocyte membranes, but it does not specifically link neuronal PUFAs to neuronal lipofuscin formation. The “Lipofuscin in neurodegeneration” section calls lipofuscin a hallmark of cellular aging, and “Altered cellular proteostasis” describes its accumulation in lysosomes. Page numbers are unavailable in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

CE(20:4) is one of the most abundant CE species in human plasma.

“Given that CE(20:4) is one of the most abundant CE species in human plasma34, we measured CE(20:4) levels in human CSF samples and detected elevated CE(20:4) in AD patients compared to age-matched control (Figure S5A).”

• cites [34] Godoy-Corchuelo, 2022, Lipid metabolic alterations in the ALS-FTD spectrum of disorders, Biomedicines sourceSupported

May combine two claims.

The CNS primarily contains HDL-like particles, many of which harbor ApoE and can engage LDLR.

“the CNS primarily contains HDL-like particles, many of which harbors ApoE and can thus engage LDLR56.”

• cites [56] Merrill, 2023, Human cerebrospinal fluid contains diverse lipoprotein subspecies enriched in proteins implicated in central nervous system health, Sci. Adv. sourcePartly supported

  The Introduction describes CSF lipoproteins as HDL-like and says APOE is their primary scaffold protein; the Discussion reports that APOE co-elutes with the bulk of CSF lipid. But the paper does not say these particles engage LDLR, and its Results place the bulk of CSF lipoprotein lipid between the plasma VLDL/LDL and large-HDL size ranges, rather than establishing that the CNS primarily contains HDL-sized particles. Page numbers were not available in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

HPLC-based heparin binding assay on non-lipidated ApoE demonstrated impaired heparin binding by the Christchurch mutation on both ApoE3 and ApoE4 background with overall ranking ApoE4 > ApoE3 > ApoE4ch > ApoE2 > ApoE3ch > K146E ApoE4.

“Consistent with the literature24, HPLC-based heparin binding assay performed on non-lipidated ApoE demonstrated impaired heparin binding by the Christchurch mutation on both ApoE3 and ApoE4 background with the overall ranking of ApoE4 > ApoE3 > ApoE4ch > ApoE2 > ApoE3ch > K146E ApoE4 (Figure S7A).”

• cites [24] Arboleda-Velasquez, 2019, Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report, Nat. Med. sourcePartly supported

  The paper’s heparin-binding discussion reports that ApoE3 Christchurch had the lowest binding among the isoforms it tested, supporting impaired binding on an ApoE3 background. Its Methods section describes heparin-sepharose chromatography, not HPLC, and lists only ApoE2, ApoE3, ApoE4, and ApoE3 Christchurch; it does not establish the claimed ApoE4 Christchurch or K146E ApoE4 comparisons or the full ranking. Page numbers are not available in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

ApoE2 and the Christchurch variant are associated with lower LDL or ApoB levels.

“with ApoE2 and Christchurch variant associated with lower LDL51 or ApoB levels52”

• cites [51] Rasmussen, 2023, APOE and vascular disease: sequencing and genotyping in general population cohorts, Atherosclerosis sourcePartly supported

  Section 3.2 reports that LDL cholesterol and apolipoprotein B are lower for APOE ε2 genotypes than for ε33. The Discussion mentions the Christchurch variant in relation to Alzheimer disease, but does not report lower LDL or ApoB levels for that variant. No page numbers were available in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [52] He, 2023, Characterization of APOE Christchurch carriers in 455,306 UK Biobank participants, Mol. Neurodegener. sourceSupported

Classified as probably not a substantial claim.

LDLR has important roles in modulating AD pathologies, in part via uptake and clearance of Aβ by astrocytes.

“important roles were shown for LDLR in modulating AD pathologies57–59, in part via uptake and clearance of Aβ by astrocytes60.”

• cites [57] Kim, 2009, Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance, Neuron sourceSupported
• cites [58] Katsouri, 2011, Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model, PLoS One sourceSupported
• cites [59] Shi, 2021, Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms, Neuron sourceSupported
• cites [60] Basak, 2012, Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Abeta uptake and degradation by astrocytes, J. Biol. Chem. sourceNot checked — no full text of the source

May combine two claims.

Similar to ApoE2, Christchurch (R136S) mutation is protective in autosomal dominant AD cases and AD mouse models.

“Similar to ApoE2, Christchurch (R136S) mutation is protective in autosomal dominant AD cases24,25 and AD mouse models26,27.”

• cites [24] Arboleda-Velasquez, 2019, Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report, Nat. Med. sourcePartly supported

  The Abstract (page not supplied) describes one person with autosomal dominant Alzheimer’s disease who was homozygous for APOE3 Christchurch (R136S) and remained free of clinical impairment for nearly three decades beyond the typical onset age. It identifies the variant as the best candidate for her resistance, but acknowledges that other factors may have contributed; it does not establish protection across multiple cases. The mouse-model claim is assigned to separate citations (26, 27), not this paper. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [25] Quiroz, 2024, APOE3 Christchurch heterozygosity and autosomal dominant Alzheimer's disease, N. Engl. J. Med. sourceSupported
• cites [26] Chen, 2024, APOE3ch alters microglial response and suppresses Abeta-induced tau seeding and spread, Cell sourceNot checked — no full text of the source
• cites [27] Nelson, 2023, The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation, Nat. Neurosci. sourceSupported

Classified as probably not a substantial claim.

Lysosomal clustering is associated with lysosomal impairment.

“a phenotype previously observed in association with lysosomal impairment41,42”

• cites [41] Henry, 2015, Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression, Hum. Mol. Genet. sourceSupported
• cites [42] Li, 2016, A molecular mechanism to regulate lysosome motility for lysosome positioning and tubulation, Nat. Cell Biol. sourceSupported

May combine two claims.

CE is upregulated in AD patient brain and various AD models, and its downregulation is protective in various AD models.

“based on its upregulation in AD patient brain and various AD models, along with the fact that its downregulation is protective in various AD models10,12,15,64.”

• cites [10] Litvinchuk, 2024, Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist, Neuron sourceNot checked — no full text of the source
• cites [12] Blanchard, 2022, APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes, Nature sourcePartly supported

  The Introduction (page unavailable) reports increased cholesteryl esters in APOE4-derived oligodendroglia and evidence of an increase in APOE4-carrier brain tissue, but it does not establish a general increase in AD patient brains or various AD models. It also reports that cyclodextrin reduced cholesterol droplets and improved myelination and cognition in APOE4 models; it does not show that downregulating cholesteryl esters was protective across various AD models. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [15] van der Kant, 2019, Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-beta in iPSC-derived Alzheimer's disease neurons, Cell Stem Cell sourceSupported
• cites [64] Shibuya, 2015, ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease, Future Med. Chem. sourceNot checked — no full text of the source

• AssumptionRests on an assumption: CE is the main transport and storage form of cholesterol.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Lipofuscin is a pathological autofluorescent lipopigment that relates to neuronal aging and vulnerability in AD brain.

“a pathological autofluorescent lipopigment of obscure origin since its discovery in 1840 (reviewed in ref.43) that relates to neuronal aging35,43 and vulnerability in AD brain44”

• cites [43] Seehafer, 2006, You say lipofuscin, we say ceroid: defining autofluorescent storage material, Neurobiol. Aging sourceNot checked — no full text of the source
• cites [35] Moreno-García, 2018, An overview of the role of lipofuscin in age-related neurodegeneration, Front. Neurosci. sourceSupported
• cites [44] Braak, 2000, Vulnerability of select neuronal types to Alzheimer's disease, Ann. N. Y. Acad. Sci. sourceNot checked — no full text of the source

May combine two claims.

Neurons are vulnerable to toxic lipids, such as oxidized lipids, particularly when lysosomes are compromised.

“neurons are vulnerable to toxic lipids, such as oxidized lipids65,66, particularly when lysosomes are compromised67.”

• cites [65] Liu, 2015, Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration, Cell sourceSupported
• cites [66] Dong, 2021, Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia, Nat. Neurosci. sourceNot checked — no full text of the source
• cites [67] Tian, 2021, Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis, Nat. Neurosci. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

APOE4 expression in human iMG induces secretion of lipids, which promotes tau phosphorylation in neurons.

“APOE4 expression in human iMG was shown to induce secretion of lipids, which promoted tau phosphorylation in neurons63.”

• cites [63] Haney, 2024, APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia, Nature sourcePartly supported

  The ‘LD+ iMG induce pTau and apoptosis in neurons’ section reports that conditioned media from lipid-high APOE4/4 human iMG induced neuronal Tau phosphorylation. But APOE3/3 iMG media had a similar effect, and the Discussion describes lipid transfer from microglia to neurons as a hypothesis, not an established cause of the phosphorylation. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Other lipids and proteins, such as ApoE receptors, may also be involved in brain lipofuscinosis.

“However, other lipids and proteins, such as ApoE receptors themselves given their sensitivity to peroxidation-derived reactive species72, may also be involved.”

• cites [72] Ramsden, 2022, Lipid peroxidation induced ApoE receptor-ligand disruption as a unifying hypothesis underlying sporadic Alzheimer's disease in humans, J. Alzheimers Dis. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Lipofuscin is a key pathology in neuronal ceroid lipofuscinosis and GRN-linked frontotemporal dementia.

“While lipofuscin is key pathology in neuronal ceroid lipofuscinosis and GRN-linked frontotemporal dementia”

• cites [68] Ward, 2017, Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis, Sci. Transl. Med. sourceSupported
• cites [69] Radke, 2015, Human NCL neuropathology, Biochim. Biophys. Acta sourcePartly supported

  The Light microscopy section calls lipopigment formation a hallmark of neuronal ceroid lipofuscinosis. The GRN entry in Table 3 concerns a form of NCL; neither it nor the passages found for “frontotemporal dementia” establish lipofuscin as a key pathology in GRN-linked frontotemporal dementia. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [70] Simon, 2023, Lysosomal functions of progranulin and implications for treatment of frontotemporal dementia, Trends Cell Biol. sourceNot checked — no full text of the source
• cites [71] Klein, 2023, Converging links between adult-onset neurodegenerative Alzheimer's disease and early life neurodegenerative neuronal ceroid lipofuscinosis?, Neural Regen. Res. sourcePartly supported

  The Neuronal Ceroid Lipofuscinosis section calls lipofuscin accumulation the pathological hallmark of NCL. The Links to other neuronal diseases section reports accumulation of NCL-like storage material in patients with GRN-linked frontotemporal lobar degeneration, but does not establish lipofuscin as a key pathology of that condition. Page numbers are unavailable in our copy. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Poorly lipidated ApoE may seed Aβ due to its propensity to aggregate, and lipidated ApoE is protective in AD models.

“Studies suggest poorly lipidated ApoE may seed Aβ due to its propensity to aggregate and that lipidated ApoE is protective in AD models1.”

• cites [1] Martens, 2022, ApoE Cascade Hypothesis in the pathogenesis of Alzheimer's disease and related dementias, Neuron sourcePartly supported

  The ‘ApoE oligomerization’ section says lipid-free apoE is prone to self-aggregation and that lipidation hinders aggregation. The ‘Phenotypic phase’ section reports that apoE promotes Aβ aggregation in mice and that increased apoE lipidation reduces Aβ deposition. These passages support the protective-lipidation point, but do not establish the specific proposed mechanism that poorly lipidated apoE seeds Aβ because it aggregates. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Drusen, the autofluorescent lipid particles prominent in the diseased eye, accumulate and likely oxidize extracellularly.

“since drusen, the autofluorescent lipid particles that are prominent in the diseased eye, accumulate and likely oxidize extracellularly74.”

• cites [74] Toops, 2016, Apolipoprotein E isoforms and AMD, Adv. Exp. Med. Biol. sourcePartly supported

  Section 1.3.3 (p. 5) describes drusen as lipid-rich lesions in Bruch’s membrane characteristic of AMD, and section 1.4 (p. 5) says oxidized cholesterol is a core component. The copy does not describe drusen as autofluorescent or say that they likely oxidize after accumulating extracellularly. (LLM, conf=0.83)

  Experimental — accuracy not yet measured

May combine two claims.

While both LDLR KO and LRP1 KO HAP1 cells demonstrated partially impaired uptake of lipApoE at 5-6 h, only LDLR KO cells showed dramatically reduced pHrodo signals for lipApoE3/E4 at 1 d.

“While both LDLR KO and LRP1 KO HAP1 cells demonstrated partially impaired uptake of lipApoE at 5–6 h, only LDLR KO cells showed dramatically reduced pHrodo signals for lipApoE3/E4 at 1 d.”

May combine two claims.

LipApoE2 raised surface LDLR in H4 and, more prominently, APOE KO iAstrocytes.

“Interestingly, lipApoE2 raised surface LDLR in H4 and, more prominently, APOE KO iAstrocytes (Figure 2A–D).”

May combine two claims.

In human APOE KO iPSC-derived astrocytes, pHrodo-lipApoE uptake showed similar isoform trend that was abolished by blocking uptake of lipApoE3/E4 with LDLR ECD.

“Lastly, in human APOE KO iPSC-derived astrocytes (iAstrocytes), pHrodo-lipApoE uptake showed similar isoform trend that was abolished by blocking uptake of lipApoE3/E4 with LDLR ECD (Figure S1I–J), validating findings in a CNS cell type.”

May combine two claims.

In H4, WT HAP1, and APOE KO iAstrocytes, incubation with lipApoE3/E4 significantly reduced surface LDLR relative to lipApoE2, revealing impaired LDLR recycling accompanying increased LDLR-mediated lipApoE uptake.

“In H4, WT HAP1, and APOE KO iAstrocytes, incubation with lipApoE3/E4 significantly reduced surface LDLR relative to lipApoE2, revealing impaired LDLR recycling accompanying increased LDLR-mediated lipApoE uptake (Figure 2A–D, Figure S2A–B).”

May combine two claims.

In serum-starved H4 cells co-treated with lipApoE and DiI-LDL for 3-4 h, lipApoE3 and lipApoE4 inhibit DiI-LDL uptake by 60-65%, whereas lipApoE2 has no effect.

“When cells were co-treated with lipApoE and DiI-LDL for 3–4 h, both lipApoE3 and lipApoE4 led to 60–65% inhibition of DiI-LDL uptake, likely via a direct competition with LDL for LDLR binding, whereas lipApoE2 had no effect (Figure 2J, L).”

May combine two claims.

In both H4 cells and APOE KO iAstrocytes, ApoE3/E4 treatment upregulates ABCA1 and ABCG1 and downregulates HMGCR, SREBF2, DHCR7, and LDLR.

“In both cell types, ApoE3/E4 treatment, which caused higher CE uptake, upregulated expression of ABCA1 and ABCG1, genes involved in cholesterol efflux, while genes mediating cholesterol synthesis (HMGCR, SREBF2 and DHCR7) were downregulated, as was LDLR (Figure 3E, Figure S3H).”

May combine two claims.

While all 3 ApoE isoforms impacted LDLR mRNA levels, lipApoE3/E4 abrogated the expected increase in surface LDLR by impairing its recycling.

“While all 3 ApoE isoforms impacted LDLR mRNA levels, lipApoE3/E4 abrogated the expected increase in surface LDLR by impairing its recycling.”

May combine two claims.

Cell-associated ApoE immunoreactivity extensively colocalized with LDLR puncta outside of transferrin-labeled recycling endosomes, suggesting "trapping" of LDLR by ApoE in other endolysosomal compartments.

“Cell-associated ApoE immunoreactivity extensively colocalized with LDLR puncta (Figure 2G) outside of transferrin-labeled recycling endosomes (Figure S2D), suggesting “trapping” of LDLR by ApoE in other endolysosomal compartments.”

May combine two claims. The quote only partly states this claim.

ApoE4-potentiated lipofuscinosis was elevated in vulnerable brain regions of a tauopathy mouse model, with exacerbation by tau pathology.

“Lipofuscin increased lysosomal accumulation of tau fibrils and was elevated in APOE4 mouse brain with exacerbation by tau pathology.”

• Also stated in: § INTRODUCTION · plain

  “ApoE4-potentiated lipofuscinosis was also observed in vulnerable brain regions of a tauopathy mouse model.”

May combine two claims.

SPR revealed high affinity LDLR binding for both lipApoE4 and lipApoE3 (KD = 9 nM and 16 nM, respectively), whereas lipApoE2-LDLR affinity was ~50-fold lower than lipApoE3 (KD = 800 nM).

“SPR similarly revealed a high affinity LDLR binding for both lipApoE4 and lipApoE3 (KD = 9 nM and 16 nM, respectively), whereas the lipApoE2-LDLR affinity was ~50-fold lower than lipApoE3 (KD = 800 nM; Figure 1D).”

May combine two claims.

ApoE2-mediated pHrodo-HDL uptake is blocked by heparin and minimally inhibited by LDLR ECD.

“Interestingly, the low pHrodo-HDL uptake mediated by ApoE2 was blocked by heparin while minimally inhibited by LDLR ECD, suggesting shifted dependency to HSPGs for ApoE2 due to impaired LDLR binding (Figure 3C, Figure S3B, C).”

May combine two claims.

A subset of BODIPY signals appeared as cytoplasmic puncta that colocalized with PLIN2, a lipid droplet marker, and mirrored total BODIPY signals.

“Interestingly, a subset of BODIPY signals appeared as cytoplasmic puncta that colocalized with PLIN2, a lipid droplet marker (Figure S3E), and mirrored total BODIPY signals (Figure S3G).”

May combine two claims.

ApoE isoform differences were manifested in the differential levels of internalized lipApoE (ApoE4 > ApoE3 > ApoE2), giving rise to the same isoform trend for LAMP1-positive vesicles containing ApoE immunoreactivity.

“ApoE isoform differences were manifested in the differential levels of internalized lipApoE (ApoE4 > ApoE3 > ApoE2), giving rise to the same isoform trend for LAMP1-positive vesicles containing ApoE immunoreactivity (Mander’s coefficients = 0.266 ± 0.045 for ApoE2, 0.410 ± 0.049 for ApoE3, 0.497 ± 0.090 for ApoE4) (Figure 2I).”

May combine two claims.

In H4 cells treated with DiI-conjugated LDL, DiI-LDL showed minimal colocalization with LDLR but significant overlap with LAMP1 immunoreactivity, consistent with rapid endosomal dissociation of LDLR from LDL, with the latter targeted to lysosomes.

“In contrast, H4 cells treated with DiI-conjugated LDL (DiI-LDL) showed minimal colocalization of DiI-LDL with LDLR (Figure S2E) but significant overlap with LAMP1 immunoreactivity (Figure S2F), consistent with rapid endosomal dissociation of LDLR from LDL, with the latter targeted to lysosomes.”

May combine two claims.

Immunostaining of total LDLR in H4 cells after lipApoE3/E4 treatment showed a modest but significant reduction in signals, which also appeared slightly more clustered.

“Immunostaining of total LDLR (cell surface + intracellular) in H4 cells after lipApoE3/E4 treatment showed a modest but significant reduction in signals, which also appeared slightly more clustered (Figure 2E–F).”

May combine two claims.

Super-resolution imaging on APOE KO iAstrocytes confirmed internalized lipApoE completely colocalized with endogenous LDLR, largely inside LAMP1 compartments.

“Super-resolution imaging on APOE KO iAstrocytes confirmed internalized lipApoE completely colocalized with endogenous LDLR (Mander’s coefficient for ApoE puncta with colocalizing LDLR = 1 for all 3 isoforms), largely inside LAMP1 compartments (Figure 2H) (Mander’s coefficients for ApoE puncta with colocalizing LAMP1 = 0.823 ± 0.061 for ApoE2; 0.903 ± 0.024 for ApoE3; 0.900 ± 0.008 for ApoE4).”

May combine two claims.

The most prominent lipid differences were observed for various CE species, PC or PE with long chains of PUFAs, and multiple TGs, which exhibited a trend of ApoE4 ≥ ApoE3 > ApoE2.

“The most prominent differences were observed for various CE species, phosphatidylcholine (PC) or phosphatidylethanolamine (PE) with long chains of polyunsaturated fatty acids (PUFAs), and multiple triglycerides (TG), which exhibited a trend of ApoE4 ≥ ApoE3 > ApoE2.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

CE(20:4)-lipApoE particles appeared more heterogeneous than POPC-lipApoE, with diameters ranging from 10 to 40 nm, albeit with no appreciable isoform differences.

“Likely reflecting variable incorporation of CE(20:4) into the core, CE(20:4)-lipApoE particles appeared more heterogeneous than POPC-lipApoE, with diameters ranging from 10 to 40 nm, albeit with no appreciable isoform differences (Figure S5C, compared with Figure S1B).”

May combine two claims.

Despite similar CE uptake induced by ApoE3 and ApoE4, ApoE4 caused significantly higher secretion of the above-mentioned cytokines.

“Despite a similar CE uptake induced by ApoE3 and ApoE4, the latter caused significantly higher secretion of the above-mentioned cytokines.”

May combine two claims.

LDLR ECD prevented the ApoE4-induced lipid burden and largely reverted gene expression changes observed with ApoE4.

“Lastly, LDLR ECD prevented the ApoE4-induced lipid burden and largely reverted gene expression changes observed with ApoE4, although several pathways showed exacerbated ApoE4 effects (e.g., oxidative phosphorylation and mitotic spindle in Figure 4F), possibly due to effects related to blocking ApoE-independent LDLR functions.”

May combine two claims.

ApoE isoform-dependent lipofuscin accumulation was replicated in WT H4 and HAP1 cells, similarly blocked by LDLR ECD or KO of LDLR, but not LRP1.

“ApoE isoform-dependent lipofuscin accumulation was replicated in WT H4 and HAP1 cells, similarly blocked by LDLR ECD or KO of LDLR, but not LRP1 (Figure 5H–I, Figure S5H–I).”

May combine two claims.

Lipofuscin appeared mostly perikaryal and localized in LAMP1-positive lysosomes.

“Lipofuscin appeared mostly perikaryal and localized in LAMP1-positive lysosomes shown by super-resolution imaging (Figure 5C).”

May combine two claims.

At 7 d, lipofuscin induced by CE(20:4)-lipApoE3/E4 was weakly detectable, while signals for CE(20:4)-ApoE2 were minimal.

“At 7 d, lipofuscin induced by CE(20:4)-lipApoE3/E4 was weakly detectable, while signals for CE(20:4)-ApoE2 were minimal.”

May combine two claims.

Co-labeling near the injection site revealed lipofuscin in both neurons and microglia but significantly more in microglia than in neurons.

“Furthermore, co-labeling with neuronal and microglial markers near the injection site in the cortex and hippocampus revealed lipofuscin in both cell types but significantly more in microglia than in neurons (Figure S6C–D), perhaps reflecting microglial activation caused by injection-induced physical damage.”

May combine two claims.

CE(20:4)-lipApoE remained largely soluble at pH 7.4 but aggregated at pH 4.5 after 4 d incubation at 37°C.

“CE(20:4)-lipApoE remained largely soluble and mostly recovered in the supernatant fraction upon incubation at pH 7.4, but abundant protein was found in the pellet fraction indicative of aggregation after incubation at pH 4.5, which mimics lysosomal pH (Figure 5O–P).”

• AssumptionThe authors state this as an assumption: pH 4.5 mimics lysosomal pH.

May combine two claims.

CE(18:1)-lipApoE4 did not induce lipofuscin because CE(18:1) is not prone to peroxidation.

“To confirm the effect of PUFA-CE-lipApoE4 on tau pff accumulation is causally linked to lipofuscin, we directly compared CE(20:4)-lipApoE4 with CE(18:1)-lipApoE4, which did not induce lipofuscin as CE(18:1) is not prone to peroxidation (Figure 6J–K).”

• AssumptionThe authors state this as an assumption: CE(18:1) is not prone to peroxidation.

May combine two claims.

Treatment of LPS-stimulated APOE KO iMg with ApoE3/E4 enhanced BODIPY-CE uptake relative to ApoE2, and LDLR ECD completely reversed the effect of ApoE4.

“Treatment of LPS-stimulated APOE KO iMg with ApoE3/E4 enhanced BODIPY-CE uptake relative to ApoE2 and LDLR ECD completely reversed the effect of ApoE4 (Figure 4A–B).”

May combine two claims.

CE(20:4)-ApoE2 exhibited the highest aggregation at pH 7.4 but comparable aggregation as CE(20:4)-ApoE4 at pH 4.5.

“CE(20:4)-ApoE2 exhibited the highest aggregation at pH 7.4 but comparable aggregation as CE(20:4)-ApoE4 at pH 4.5 (Figure 5O–Q, Figure S5K).”

May combine two claims.

LDLR-mediated uptake of lipApoE3 and lipApoE4 leads to endolysosomal trapping of LDLR and depletion of cell surface LDLR.

“LDLR-mediated uptake of lipApoE3 and lipApoE4 led to endolysosomal trapping of LDLR and depletion of cell surface LDLR”

May combine two claims.

Lipofuscinosis was observed with endogenous expression of APOE in APOE4 KI mouse brains, where it was worsened by P301S MAPT expression and ameliorated by an LXR agonist previously shown to reduce brain PUFA-CE.

“Lipofuscinosis was also observed with endogenous expression of APOE in APOE4 KI mouse brains, where it was worsened by P301S MAPT expression and ameliorated by an LXR agonist previously shown to reduce brain PUFA-CE10.”

• cites [10] Litvinchuk, 2024, Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist, Neuron sourceNot checked — no full text of the source

May combine two claims.

LipApoE2 does not cause endolysosomal trapping of LDLR or depletion of cell surface LDLR due to defective LDLR binding.

“LipApoE2 did not show these effects due to defective LDLR binding.”

Probably not a substantial claim: may not pass S3 (load-bearing).

An overall trend of ApoE4 >= ApoE3 > ApoE2 was observed in lipApoE uptake.

“The exact uptake efficiency of ApoE4 vs. ApoE3 varies across different lipidation batches, but an overall trend of ApoE4 >= ApoE3 > ApoE2 was observed.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The exact uptake efficiency of ApoE4 versus ApoE3 varies across different lipidation batches.

“The exact uptake efficiency of ApoE4 vs. ApoE3 varies across different lipidation batches, but an overall trend of ApoE4 >= ApoE3 > ApoE2 was observed.”

May combine two claims.

Inhibition of lysosomal acid lipase broadly increases levels of CE including CE(20:4) and exacerbates lipofuscinosis only in the presence of lipApoE.

“Inhibition of lysosomal acid lipase, which broadly increased levels of CE including CE(20:4), exacerbated lipofuscinosis, but only in the presence of lipApoE.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Lipofuscin was detected in a broad spectrum but appeared the most intense in the 488 nm channel.

“Lipofuscin was detected in a broad spectrum but appeared the most intense in the 488 nm channel, which was used for image capture and quantification.”

May combine two claims.

Impaired LDLR binding of lipApoE2 results in decreased LDLR-mediated uptake of ApoE and associated lipids, including CE, thereby preventing excessive activation of microglia.

“In this study, we demonstrate impaired LDLR binding of lipApoE2 results in decreased LDLR-mediated uptake of ApoE and associated lipids, including CE, thereby preventing excessive activation of microglia.”

May combine two claims.

While multiple receptors mediate lipApoE internalization, LDLR plays a dominant role with longer-term treatment.

“Therefore, while multiple receptors mediate lipApoE internalization, LDLR plays a dominant role with longer-term treatment.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Formation of homogeneous ApoE nanodiscs with a 10-20 nm diameter was confirmed by negative stain transmission electron microscopy, with no appreciable isoform-specific differences.

“Formation of homogeneous ApoE nanodiscs with a 10–20 nm diameter was confirmed by negative stain transmission electron microscopy, with no appreciable isoform-specific differences (Figure S1B).”

May combine two claims.

ApoE3/E4 promotes internalization of BODIPY-CE via HDL, which otherwise sequesters BODIPY-CE extracellularly.

“Pre-complexing BODIPY-CE/HDL with ApoE3 or ApoE4, but not ApoE2, produced higher intracellular BODIPY signals, suggesting ApoE3/E4 promotes internalization of BODIPY-CE via HDL, which otherwise sequesters BODIPY-CE extracellularly.”

May combine two claims.

The cholesterol-efflux role of ApoE2 outweighs its lipid uptake function, leading to an overall reduction in cholesterol burden.

“Notably, most CE species were lowered with ApoE2 treatment compared to the no-ApoE control, suggesting the cholesterol-efflux role of ApoE2 outweighs its lipid uptake function, leading to an overall reduction in cholesterol burden.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Several pathways showed exacerbated ApoE4 effects with LDLR ECD, possibly due to effects related to blocking ApoE-independent LDLR functions.

“Lastly, LDLR ECD prevented the ApoE4-induced lipid burden and largely reverted gene expression changes observed with ApoE4, although several pathways showed exacerbated ApoE4 effects (e.g., oxidative phosphorylation and mitotic spindle in Figure 4F), possibly due to effects related to blocking ApoE-independent LDLR functions.”

Probably not a substantial claim: may not pass S3 (load-bearing).

BODIPY-CE uptake results were replicated using APOE KO iMg from a different round of differentiation.

“BODIPY-CE uptake results were replicated using APOE KO iMg from a different round of differentiation (Figure S4B–C).”

May combine two claims.

LXR agonist dosing significantly decreased PUFA-CE species [CE(18:2), CE(20:4), CE(20:5) and CE(22:6)] that accumulated in Tau/E4 mouse brain, accompanied by reduced tau pathology and neurodegeneration.

“Our recent study demonstrated LXR agonist dosing significantly decreased PUFA-CE species [CE(18:2), CE(20:4), CE(20:5) and CE(22:6)] that accumulated in Tau/E4 mouse brain, accompanied by reduced tau pathology and neurodegeneration10.”

• cites [10] Litvinchuk, 2024, Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist, Neuron sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

LDLR primarily mediates lipid metabolism.

“LDLR, which primarily mediates lipid metabolism50.”

• cites [50] Beglova, 2005, The LDL receptor: how acid pulls the trigger, Trends Biochem. Sci. sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Lower LDL/ApoB levels correlate with lower cardiovascular disease risk.

“a profile that correlates with lower cardiovascular disease risk53.”

• cites [53] Wadhera, 2016, A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality, J. Clin. Lipidol. sourceNot checked — no full text of the source

May combine two claims.

The study provides a mechanistic framework potentially clarifying ApoE isoform-dependent impact on LOAD risk, implicating receptor-mediated internalization of ApoE and associated pathogenic lipid cargoes.

“Our study provides a mechanistic framework potentially clarifying ApoE isoform-dependent impact on LOAD risk, implicating receptor-mediated internalization of ApoE and associated pathogenic lipid cargoes.”

May combine two claims.

Reduced LDLR binding by lipApoE2 lowered its cellular uptake and that of its lipid cargoes, preventing excessive intracellular lipid burden observed with lipApoE3/E4.

“Pertinent to ApoE’s physiological function of lipid transport, reduced LDLR binding by lipApoE2 lowered its cellular uptake and that of its lipid cargoes, preventing excessive intracellular lipid burden observed with lipApoE3/E4.”

• AssumptionRests on an assumption: ApoE’s physiological function is lipid transport.

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

ApoE isoforms differentially perturb endosomal recycling of receptors such as LRP8/ApoER2, with ApoE4 having a deleterious impact on reelin signaling.

“Previous work showed ApoE isoforms differentially perturb endosomal recycling of receptors, such as LRP8/ApoER2, with a deleterious impact of ApoE4 on signaling by reelin, a key ligand of this receptor49.”

• cites [49] Lane-Donovan, 2017, The ApoE receptors Vldlr and Apoer2 in central nervous system function and disease, J. Lipid Res. sourceNot checked — no full text of the source

May combine two claims.

Reduced LDLR binding of ApoE2 may free up LDLR for binding and clearance of other ligands, including Aβ, thus decreasing amyloid pathology.

“Therefore, reduced LDLR binding of ApoE2 may free up LDLR for binding and clearance of other ligands, including Aβ, thus decreasing amyloid pathology.”

• AssumptionRests on an assumption: LDLR’s ligands in the CNS, besides ApoE, are not well defined.

May combine two claims.

PUFA-CE-lipApoE-induced lipofuscinosis mirrored the ApoE2 < ApoE3 < ApoE4 allelic series, involved lipid peroxidation of PUFA-CE and perturbed lysosomes, with an impact on lysosomal accumulation of tau pffs.

“PUFA-CE-lipApoE-induced lipofuscinosis mirrored the ApoE2 < ApoE3 < ApoE4 allelic series, involved lipid peroxidation of PUFA-CE and perturbed lysosomes, with an impact on lysosomal accumulation of tau pffs.”

Classified as probably not a substantial claim.

An LXR agonist was previously shown to decrease PUFA-CE, including CE(20:4).

“an LXR agonist previously shown to decrease PUFA-CE, including CE(20:4)10”

• cites [10] Litvinchuk, 2024, Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist, Neuron sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

CE(20:4)/POPC-lipidated ApoE4 used for mouse brain injection had an endotoxin level < 10 EU/mg.

“CE(20:4)/POPC-lipidated ApoE4 used for mouse brain injection had an endotoxin level < 10 EU/mg.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Human CSF samples were obtained with informed consent under approved IRB protocols.

“The samples were obtained with informed consent under WIRB® protocol #20081324 and #20100229 as well as protocols 7005, 8009, and 8200, reviewed and approved by their Institutional Review Board.”

Probably not a substantial claim: may not pass S3 (load-bearing).

All ApoE preparations used in iMg experiments had endotoxin levels < 1 EU/mg.

“All ApoE preparations used in iMg experiments had endotoxin levels < 1 EU/mg.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The study cannot rule out contributions of other ApoE receptors to isoform-dependent phenotypes.

“we cannot rule out contributions of other ApoE receptors to isoform-dependent phenotypes.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The study focuses on ApoE isoform-dependent effects downstream of ApoE-LDLR interaction without addressing the source of lipApoE in the brain.

“Our study focuses on ApoE isoform-dependent effects downstream of ApoE-LDLR interaction without addressing the source of lipApoE in the brain (e.g., astrocytes or microglia).”

May combine two claims.

Inhibiting lipApoE-receptor interactions in the CNS may reduce LOAD risk or disease progression, in part by decreasing formation of lipofuscin and promoting lysosomal health.

“inhibiting lipApoE-receptor interactions in the CNS may reduce LOAD risk or disease progression, in part by decreasing formation of lipofuscin and promoting lysosomal health.”